Novo Nordisk Launches Wegovy Pill in US, Intensifying Weight-Loss Drug Price War

Novo Nordisk has launched its Wegovy weight-loss pill in the United States.
The drug is the first and only GLP-1 weight-loss pill currently available on the market.
It costs significantly less than injectable GLP-1 treatments.
Self-paying patients can buy the starting dose for $149 per month.
Injectable weight-loss drugs often cost around $1,000 per month.
The pill offers a needle-free option that may appeal to more patients.
Novo hopes the launch will help regain market share amid rising competition.
Its main rival is Eli Lilly, which sells Mounjaro and Zepbound injections.
Novo’s share price rose after the announcement despite recent declines.
The Wegovy pill is currently approved only in the United States.
The UK regulator is reviewing approval and may decide later this year.